Literature DB >> 26171014

Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue.

Qingjun Lu1, Jieshu Wang1, Gang Yu1, Tianhua Guo1, Chun Hu2, Peng Ren1.   

Abstract

The activation of mammalian target of rapamycin (mTOR) has been reported in tumor development, but the role of mTOR in colorectal carcinomas remains unclear. The aim of the present study was to investigate the significance of mTOR and its downstream effector 70 kDa ribosomal protein S6 kinase (P70S6K) in human colorectal carcinomas. The phosphorylated (p-)mTOR and p-P70S6K proteins were examined by immunohistochemistry performed on tissue microarray containing tissue samples obtained from colorectal carcinoma (n=111), adenomatous polyps (n=40) and normal colonic mucosa (n=40), with a comparison between the expression of these proteins and the clinicopathological parameters of patients with carcinomas. The positive expression rates of p-mTOR and p-P70S6k were 60.4 and 65.8%, respectively, in colorectal carcinoma tissue, which was significantly increased compared with the tissue from adenomatous polyps (27.5 and 20%, respectively) and normal colonic mucosa (10.0 and 5.0%, respectively) (P<0.05). Overexpression of the p-mTOR and p-P70S6K proteins was significantly associated with the tumor-node-metastasis stage, the occurrence of distal and lymph node metastasis and the degree of differentiation. Aberrant expression of p-mTOR and p-P70S6K may contribute to the pathogenesis, growth, invasion and metastasis of colorectal carcinoma. The phosphorylation of these proteins was considered to be a promising marker to indicate the aggressive behaviors and prognosis of colorectal carcinomas. The overexpression of the mTOR/P70S6K signaling pathway may play an important role in colorectal carcinoma carcinogenesis. The expression of p-mTOR and p-P70S6K was considered as a promising marker to indicate the aggressive behaviors and prognosis of human colorectal carcinomas.

Entities:  

Keywords:  colorectal cancer; immunohistochemistry; mammalian target of rapamycin/70 kDa ribosomal protein S6 kinase; reverse transcription-polymerase chain reaction

Year:  2015        PMID: 26171014      PMCID: PMC4487095          DOI: 10.3892/ol.2015.3228

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

Review 1.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.

Authors:  Yong Zhang; Huan-Juan Ni; De-Yun Cheng
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.

Authors:  S Walsh; L Flanagan; C Quinn; D Evoy; E W McDermott; A Pierce; M J Duffy
Journal:  Breast       Date:  2011-09-29       Impact factor: 4.380

4.  Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Authors:  Elizabeth Buck; Alexandra Eyzaguirre; Eric Brown; Filippo Petti; Siobhan McCormack; John D Haley; Kenneth K Iwata; Neil W Gibson; Graeme Griffin
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

5.  Expression of mTOR signaling pathway markers in prostate cancer progression.

Authors:  Celeste L Kremer; Rob R Klein; Jenny Mendelson; Walden Browne; Linda K Samadzedeh; Kristie Vanpatten; Lindsey Highstrom; Gary A Pestano; Raymond B Nagle
Journal:  Prostate       Date:  2006-08-01       Impact factor: 4.104

6.  Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.

Authors:  Wei Feng; Xiuzhen Duan; Jinsong Liu; Jianguo Xiao; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

7.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Expression of mTOR protein and its clinical significance in endometrial cancer.

Authors:  Jae Hong No; Yong-Tark Jeon; In-Ae Park; Daehee Kang; Jae Weon Kim; Noh-Hyun Park; Soon-Beom Kang; Yong-Sang Song
Journal:  Med Sci Monit       Date:  2009-10

9.  Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.

Authors:  Yoh Dobashi; Shioto Suzuki; Hirochika Matsubara; Maiko Kimura; Shunsuke Endo; Akishi Ooi
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

10.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Authors:  Eric Raymond; Jérôme Alexandre; Sandrine Faivre; Karina Vera; Eric Materman; Joseph Boni; Cathie Leister; Joan Korth-Bradley; Axel Hanauske; Jean-Pierre Armand
Journal:  J Clin Oncol       Date:  2004-05-10       Impact factor: 44.544

View more
  10 in total

1.  CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.

Authors:  Sylvain Ferrandon; Jennifer DeVecchio; Leonardo Duraes; Hanumant Chouhan; Georgios Karagkounis; Jacqueline Davenport; Matthew Orloff; David Liska; Matthew F Kalady
Journal:  Cancer Res       Date:  2019-11-08       Impact factor: 12.701

2.  Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model.

Authors:  Doerte Poburski; Christiane Leovsky; Josefine Barbara Boerner; Luisa Szimmtenings; Michael Ristow; Michael Glei; René Thierbach
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

Review 3.  Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.

Authors:  Shuangjiang Li; Zhiqiang Wang; Jian Huang; Shan Cheng; Heng Du; Guowei Che; Yong Peng
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

4.  Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling.

Authors:  Ning Dou; Shijun Yu; Xiaojuan Ye; Dong Yang; Yandong Li; Yong Gao
Journal:  Oncotarget       Date:  2016-12-27

Review 5.  Targeting Protein Synthesis in Colorectal Cancer.

Authors:  Stefanie Schmidt; Sarah Denk; Armin Wiegering
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

6.  S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.

Authors:  Hua Shen; Gao-Chan Wang; Xiang Li; Xin Ge; Meng Wang; Zhu-Mei Shi; Vikas Bhardwaj; Zi-Xuan Wang; Ralph G Zinner; Stephen C Peiper; Andrew E Aplin; Bing-Hua Jiang; Jun He
Journal:  Oncogene       Date:  2020-10-09       Impact factor: 9.867

7.  Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer.

Authors:  Yanru Feng; Jialin Luo; Peng Liu; Yuan Zhu; Guoping Cheng; Linfeng Zheng; Luying Liu
Journal:  Discov Oncol       Date:  2022-02-14

8.  Improvement of the BALB/c-3T3 cell transformation assay: a tool for investigating cancer mechanisms and therapies.

Authors:  Doerte Poburski; René Thierbach
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

9.  Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway.

Authors:  Małgorzata Kapral; Joanna Wawszczyk; Katarzyna Jesse; Monika Paul-Samojedny; Dariusz Kuśmierz; Ludmiła Węglarz
Journal:  Molecules       Date:  2017-10-03       Impact factor: 4.411

10.  Origanum majorana Essential Oil Triggers p38 MAPK-Mediated Protective Autophagy, Apoptosis, and Caspase-Dependent Cleavage of P70S6K in Colorectal Cancer Cells.

Authors:  Khawlah Athamneh; Aysha Alneyadi; Halima Alsamri; Asma Alrashedi; Abdulrasheed Palakott; Khaled A El-Tarabily; Ali H Eid; Yusra Al Dhaheri; Rabah Iratni
Journal:  Biomolecules       Date:  2020-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.